Development of new environment friendly insecticides against malaria mosquito
Provider:
Grant Agency for Health Research of the Czech Republic
Investigator:
Kamil Musilek
Abstract:
Use of pesticides as a preventive measure is very important element in the integrated management approach to malaria and other vector-borne disease parasitoses. New acetylcholinesterase inhibitors, which will covalently bond to the insect specific cysteine, will be prepared. The synthesis of novel compounds and structure-biological activity relationship (SAR)
evaluation will be performed. The selected insectide candidates will be evaluated on safety after in vivo administration.
Project duration:
1-April-2016–31-December 2019
Biomedical photonic devices for advanced medicinal diagnostics and therapy
Provider:
Grant Agency for Health Research of the Czech Republic
Investigator:
Martin Kunes, Radka Czeczotkova, Jiri Paral, Pavel Peterka, Oleksiy Lyutakov
Abstract:
Proposed project involves development of novel optical system for fiber-optic based local monitoring, sensing and treatment. First, the material, to be inserted into the living mass (in-vivo experiment) will be biodegradable and biocompatible. This prevents the risk associated with traditional silica fiber. As the background, polymer blends and interpenetrating polymer networks will be used. Then, developed material will be used for construction of optical fiber and its connection with laser sources and detectors. Additionally, surface of optical fibers will be functionalized by susceptible layer for introducing the possibility for chemical analysis in-vivo. The safety and biocompatibility of developed system will be tested in a preclinical settings. Project combine specialists from different field of research and completely covered all stage of preparation of above mentioned system.
Project duration:
1-May-2015–31-December 2018
Development of multi-target drugs for Alzheimer´s disease: combination of AChE inhibitor and melatonin derivative
Provider:
Grant Agency for Health Research of the Czech Republic
Investigator:
Kamil Kuca, Jan Ricny
Abstract:
We would like to exploit the obtained preliminary data in preparation of more active hybrids combining derivative of melatonin and AChE inhibitor – huprine. Such compounds should exert multipotent profile in Alzheimer´s disease treatment by combining beneficial effect of mainly, but not exclusively, cholinergic enhancement and antioxidant activity. Funnel-like drug development process from design and synthesis though in vitro efficacy and safety evaluation to in vivo validation involving kinetic, toxic, pharmacodynamic and behavioral examination will be applied in order to select the best drug candidate. In this project, basic research (9%) represent the synthesis of novel compounds and the structure-biological activity relationship (SAR) evaluation. Applied research (91%) represents majority of the project, thus, the funnel-like selection of a drug candidate, its in vivo validation and subsequent patent protection application with commercial utilization.
Project duration:
1-May-2015–31-December 2018
Development of novel disinfectants against pathogens occuring in the hospital environment
Provider:
Grant Agency for Health Research of the Czech Republic
Investigator:
Ondrej Soukup (main investigator), David Malinak,Roman Prymula, Sarka Salajkova, Lenka Ryskova, Lenka Hobzova
Abstract:
In this project, we would like to develop new compounds based on quaternary ammonium salts with a strong disinfectant potential against nosocomial infections in hospital environment, thus bacterial, fungal and viral
pathogens. The project is designed for development of various (3-6) mixtures with strong disinfecting properties and wide spectrum of efficacy by combining individual agents with more specific efficacy. Developed mixtures also should not exert skin irritation at operating personnel, which will be ensured by in vitro and in vivo skin tests. Furthermore, variability of the mixtures and their alternating application should represent a tool for the controlling of microbial resistance. In this project, basic research (9%) represent the synthesis of novel compounds and
the structure-biological activity relationship (SAR)evaluation. Applied research (91%) represents majority of the project, thus, the funnel-like selection of a drug candidates, their in vivo safetyvalidation and subsequent patent protection application with subsequent application for patent protection.
Project duration:
1-May-2015–31-December 2018
Modulators of mitochondrial enzymes for treatment of neurodegenerative disorders
Provider:
Grant Agency for Health Research of the Czech Republic
Investigator:
Kamil Musilek, Rafael Dolezal, Martina Hrabinova, Martin Kunes, Ondrej Benek, Lukas Hroch
Co-investigator:
Zdenek Fisar, Jana Hroudova, Jiri Raboch
Abstract:
The mitochondrial enzymes seem to be next target for molecular design in term of Alzheimer Disease (AD) treatment. They are well known for their interaction with β-amyloid and they are subsequently responsible for disruption of cell homeostasis and cell death. The inhibition of β-amyloid interaction with mitochondrial enzymes by small modulators might prevent neuronal cell loss and thus improve progress of AD. Up-to-date, only few mitochondrial enzyme modulators were published and their design, synthesis and evaluation will be highly progressive in near future. The main aim of the project is development of convenient candidates (small molecules) for further preclinical research.
Project duration:
1-May-2015–31-December 2018
NT13599 - Characterization of the diagnostic potential of native polypeptides in amniotic fluid
Provider:
Ministry of Health
Investigator:
Juraj Lenčo, Marian Kacerovský, Vojtěch Tambor, Jana Žďárová Karasová
Abstract:
Preterm premature rupture of membranes (PPROM) is a principal cause of preterm births and considerably increases perinatal morbidity and mortality. The main reason is the causal link with intraamniotic infection (IAI), which occurs in 40-60% of PPROM patients. The most serious cases of IAI may result in fetal inflammatory response (FIRS) and cause permanent health consequences for the newborn or end up by the death of the fetus. FIRS is very often subclinical and thus frequently remains undetected. Currently, there is no tool for its precise prenatal diagnostics available. The project is focused on characterization of the diagnostic potential of native amniotic fluid polypeptides with regard to detection of IAI and FIRS.
Project duration:
1-April-2012 - 31-Dec-2015
NT14150 - Modulation of Colorectal Carcinoma by Biological Therapy - In Vitro Study
Provider:
Ministry of Health
Investigator:
Aleš Ryška, Stanislav John
Proteomics team - Biomedical Research Center
Abstract:
Resecated tumours from appropriate patients with colorectal carcinoma will be histopathologically examined and from the part of the tumour cancer cells will be obtained. First, the tumor cells will be cultured and the prepared cell cultures will be treated by bevacizumab and cetuximab. Subsequently, we will evaluate the changes in the phenotype of primary colorectal cancer tumor lines after stimulation with these agents in order to describe effect on the biological profile of the cells. Samples of these cell lines will be deeply frozen for the further proteomic analysis. Prospectively, in the second phase we would try to identify differences in proteome among the cell lines from patients who responded to the treatment by the particular drug from those where the treatment failed. As a result we would detect the differences both biological both proteomic which may be relevant for the future optimization and individualization of therapy.
Project duration:
1-May-2013 - 31-Dec-2015
Provider:
Ministry of Health
Investigator:
Marian Kacerovský, Ctirad Andrýs, Martin Procházka, Ondřej Šimetka, Petr Janků
Abstract:
Women with preterm prelabor rupture of membranes between gestational age 24 and 36 weeks will be included into the multicentre study. The intensity of inflammatory response (based on levels of cytokines and alarmins) and microbial load of Ureaplasma spp. will be determined in the cervical fluid. The placenta will be assessed for the signs of histological chorioamnionitis and funisitis after delivery. The inflammatory response in the cervical fluid will be characterized with respect to the presence of histological chorioamnionitis and funisitis with an ultimate goal to create a prediction model for these inflammatory complications. The relationship between microbial load of Ureaplasma spp. in cervical fluid and inflammatory response will be evaluated as well. Last goal will be to analyse the potential of microbial load of Ureaplasma spp. for the prediction of histological chorioamnionitis and funisitis.
Project duration:
1-May-2013 - 31-December-2015
Provider:
Ministry of Health
Investigator:
Jan Bureš, Daniel Jun, Marcela Kopáčová, Kamil Kuča, Martin Kuneš, Jaroslav Květina, Kamil Musílek, Stanislav Rejchrt, Ilja Tachecí, Jana Žďárová Karasová
Abstract:
Our research team will synthesise both priority compounds K203 and K027 (and reference asoxim and obidoxim) in sufficient volumes and supreme purity. Pharmacokinetics studies will set perspective therapeutic regimes (doses and rate of administration) and absorption gastrointestinal window. Bioavailability studies will determine biodistribution and effect / toxic exposition ratio in particular physiological systems. Investigation of motor functions of the upper gastrointestinal tract enables to evaluate possible therapeutic effect (against organophosphates poisoning) and possible side effects of acetylcholinesterase modulators to the gastrointestinal tract. The research team will use oesophageal impedance, pH-metry, high resolution manometry and electrogastrography. This is a priority and high impact society project.
Project duration:
1-May-2013 - 31-December-2015
